10-Q: UHP Reports Wider Q3 Loss, FDA Delays Persist

United Health Products, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, alongside ongoing FDA regulatory challenges for its CelluSTAT product and a 'going concern' warning.

Summary

• United Health Products, Inc. (UHP) incurred a net loss of $2,132,440 for the nine months ended September 30, 2025, a substantial increase from the $1,187,621 net loss in the comparable period of 2024.
• The company reported $0 in revenues for both the three and nine months ended September 30, 2025 and 2024, as it continues to focus capital and resources on obtaining Class III Premarket Approval (PMA) for its CelluSTAT hemostatic gauze.
• Operating expenses for the nine months ended September 30, 2025, increased to $1,990,751 from $1,222,174 in the prior year, primarily due to $1,120,125 in stock-based compensation from RSU vesting.
• Cash and cash equivalents significantly decreased to $18,376 as of September 30, 2025, from $168,883 at December 31, 2024.
• The company has a negative working capital of $1,963,227 as of September 30, 2025, and its independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The FDA issued a Warning Letter on March 25, 2025, identifying five violations in the 2019 clinical trial, leading to the disapproval of UHP's Investigational Device Exemption (IDE) application for a new 27-subject clinical trial on April 25, 2025.
• The Common Stock Purchase Agreement (CSPA) with White Lion, which provided the right to sell up to $10,000,000 of common stock, ended on October 1, 2025, and has not been extended.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, and the Vice President of Finance and Principal Financial Officer resigned on June 12, 2025, with the CEO, Brian Thom, acting in the interim.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress (significant losses, negative working capital, low cash, going concern warning), major regulatory setbacks with the FDA (Warning Letter, IDE disapproval), and the expiration of a key financing agreement. While management is exploring strategic options, the immediate challenges are substantial.

Positives

• Net loss for the three months ended September 30, 2025, slightly decreased to $285,594 compared to $303,662 in the same period of 2024, primarily due to a decrease in consulting expenses.
• Net cash used in operating activities for the nine months ended September 30, 2025, decreased to $633,815 from $1,013,278 in the prior year, indicating a reduction in operational cash burn.
• The company is actively engaging with the FDA and has retained a regulatory attorney to address the Warning Letter and explore options, including a new pivotal clinical trial, to advance its PMA application.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly increased to $2,132,440 from $1,187,621 in the prior year.
• The company reported $0 revenue for all periods presented, indicating no commercial sales activity.
• Cash and cash equivalents declined sharply from $168,883 at December 31, 2024, to $18,376 at September 30, 2025.
• Total liabilities increased to $3,433,856 at September 30, 2025, from $2,713,810 at December 31, 2024, while total assets decreased.
• The company has a negative working capital of $1,963,227 and faces substantial doubt about its ability to continue as a going concern.
• The FDA issued a Warning Letter for violations in the 2019 clinical trial, leading to the disapproval of the IDE application for a new study, creating significant regulatory hurdles.
• The Common Stock Purchase Agreement with White Lion, a key financing source, expired on October 1, 2025, and was not extended, limiting immediate access to equity capital.
• Disclosure controls and procedures were assessed as not effective, indicating weaknesses in financial reporting oversight.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses, negative working capital, and insufficient revenue-producing operations.
• Uncertainty regarding FDA Premarket Approval (PMA) for CelluSTAT, as the application faces a Deficiencies Letter, an unresolved Warning Letter, and disapproval of a proposed Investigational Device Exemption (IDE) application.
• Reliance on the sale of equity securities and other traditional financing sources to fund future development and working capital needs, with no assurance of adequate or favorable financing terms.
• The company has paused commercial activities to focus on PMA, meaning no current revenue generation and prolonged time to market.
• Potential for significant dilution to existing shareholders if future capital raises involve issuing more equity.
• The effectiveness of disclosure controls and procedures was deemed not effective, posing risks to the accuracy and timeliness of financial reporting.
• Competition in the Class III human surgical markets from established participants with approved hemostatic agents.

Future Outlook

The company's future outlook is highly dependent on resolving the FDA Warning Letter and securing Premarket Approval (PMA) for its CelluSTAT product for Class III human surgical markets. Management is evaluating strategic options, including a sale or merger with an industry leader or commercial partnerships, as it does not intend to pursue full commercialization independently or remain an independent company long-term. The timing for FDA resolution and commencement of any new clinical trials remains uncertain, and the company will need to raise external capital to fund ongoing operations.

Management Comments

• "We are continuing on our path to seek FDA Premarket Approval (PMA) for our CelluSTAT Hemostatic Gauze products to implement our business strategy."
• "We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term."
• "Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors... and (ii) one or more commercial partnerships with established market participants."
• "Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur."
• "We are evaluating alternatives to raise external capital to fund our operations on terms that minimize dilution to existing shareholders which may include agreements similar to the CSPA."
• Brian Thom, Principal Executive Officer, certified that the report does not contain any untrue statement of a material fact and that financial statements fairly present the financial condition, results of operations, and cash flows.

Industry Context

The company operates in the highly regulated medical device and wound care sectors, specifically targeting the Class III human surgical markets. This segment is characterized by stringent FDA approval processes, high barriers to entry, and competition from established players like Ethicon (with Surgicel Original). The company's strategy to seek a sale, merger, or commercial partnership reflects the capital-intensive nature of bringing a Class III device to market and the need for significant distribution and commercialization capabilities typically held by larger industry participants.

Comparison to Industry Standards

• The 2019 clinical trial showed statistically superior performance in time to hemostasis using CelluSTAT over Ethicon's Surgicel Original, which is noted as the current standard of care.

Management Changes

Corporate Governance

Related Party Transactions

• Convertible notes payable to related parties (Brian Thom, CEO, and Robert Denser, Director) totaling $500,000 as of September 30, 2025, with an interest rate of 13% and maturity date of December 31, 2026.
• Accrued interest on these related party convertible notes was $233,842 as of September 30, 2025.
• During the nine months ended September 30, 2025, the CEO advanced the company $20,000 for operating expenses, which was repaid in full during the same period.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and uncertainty regarding the company's ability to achieve FDA approval and commercialization, impacting share value.
• Employees may experience uncertainty due to the company's 'going concern' status and the resignation of a key financial officer.
• Creditors (including related parties) are exposed to increased risk given the company's negative working capital and substantial doubt about its ability to continue operations.
• Customers (potential future) are impacted by the delays in bringing the Class III CelluSTAT product to market due to regulatory hurdles.

Next Steps

• Resolve the FDA Warning Letter regarding the 2019 clinical trial violations.
• Engage with the FDA to find a path to timely approval of a new Investigational Device Exemption (IDE) and commencement of a new clinical trial, potentially a new pivotal study.
• Evaluate strategic options for commercialization, including a sale or merger of the company or commercial partnerships with established market participants.
• Seek new external capital to fund ongoing operations and future development activities, as the previous Common Stock Purchase Agreement has expired.
• Address the identified ineffectiveness of disclosure controls and procedures.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net losses, critically low cash reserves, negative working capital, and an explicit 'going concern' warning from auditors. Significant regulatory hurdles, including an unresolved FDA Warning Letter and disapproval of a new clinical trial, cast serious doubt on the company's ability to achieve market approval for its core product. The expiration of a key financing agreement further exacerbates liquidity concerns. While management is exploring strategic alternatives, the immediate outlook is highly unfavorable, making the stock a strong sell for any investor.

Keywords

United Health Products, UHP, CelluSTAT, hemostatic gauze, FDA approval, PMA, medical device, wound care, Class III, clinical trial, financial results, 10-Q, going concern, regulatory risk